Trial Profile
A multicenter, randomized, controlled, open-label phase II study to compare the efficacy and safety of nab-paclitaxel and docetaxel in Japanese patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2017
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Sep 2017 New trial record